A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401 by Nogami, Naoyuki et al.
1 
A Phase II Study of Amrubicin and Topotecan Combination Therapy in Patients 1 
with Relapsed or Extensive-Disease Small-Cell Lung Cancer: Okayama Lung 2 
Cancer Study Group Trial 0401 3 
 4 
Naoyuki Nogami, MD, PhD1, Katsuyuki Hotta, MD, PhD2*, Shoichi Kuyama, MD, PhD3, 5 
Katsuyuki Kiura, MD, PhD2, Nagio Takigawa, MD, PhD2, Kennichi Chikamori, MD, PhD4, 6 
Takuo Shibayama, MD, PhD5, Daizo Kishino, MD4, Shinobu Hosokawa, MD, PhD6, Akihiko 7 
Tamaoki, MD, PhD7, Shingo Harita, MD, PhD3, Masahiro Tabata, MD, PhD2, Hiroshi Ueoka, M8 
D, PhD1, Tetsu Shinkai, MD, PhD1, Mitsune Tanimoto, MD, PhD2 9 
 10 
1Department of Respiratory Medicine, NHO Shikoku Cancer Center, Matsuyama, Japan; 11 
2Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan; 3Department 12 
of Medicine, Chugoku Central Hospital, Fukuyama, Japan, 4Department of Respiratory Medicine, 13 
NHO Yamaguchi-Ube Medical Center, Ube, Japan; 5Department of Medicine, NHO 14 
Minami-Okayama Medical Center, Okayama, Japan; 6Department of Respiratory Medicine, 15 
Okayama Red Cross Hospital, Okayama, Japan; 7Department of Respiratory Medicine, Okayama 16 
Institute of Health and Prevention, Okayama, Japan  17 
 18 
Correspondence should be addressed to: Katsuyuki Hotta, M.D., Ph.D. 19 
Department of Respiratory Medicine 20 
Okayama University Hospital 21 
2-5-1, Shikata-cho, Kitaku, Okayama, 700-8558, Japan 22 
PHONE: +81-86-235-7227, FAX:+81-86-232-8226, E-mail: khotta@md.okayama-u.ac.jp 23 
 24 
Running Title: Amrubicin and topotecan for SCLC 25 
Conflict of Interest: none 26 
UMIN clinical trial registry: C000000130 27 
2 
https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&r28 
ecptno=R000000179&language=J 29 
 30 
31 
3 
Abstract 32 
Backgrounds: Chemotherapy is a mainstay in the treatment of extensive-disease 33 
small-cell lung cancer (ED-SCLC), although the survival benefit remains modest. We 34 
conducted a phase II trial of amrubicin (a topoisomerase II inhibitor) and topotecan (a 35 
topoisomerase I inhibitor) in chemotherapy-naïve and relapsed SCLC patients. 36 
Methods: Amrubicin (35mg/m2) and topotecan (0.75mg/m2) were administered on 37 
days 3–5 and 1–5, respectively. The objective response rate (ORR) was set as the 38 
primary endpoint, which was assessed separately in chemotherapy-naïve and relapsed 39 
cases. 40 
Results: Fifty-nine patients were enrolled (chemotherapy-naïve 31, relapsed 28). The 41 
ORRs were 74% and 43% in the chemotherapy-naïve and relapsed cases, respectively. 42 
Survival data were also promising, with a median progression-free survival time and 43 
median survival time of 5.3 and 14.9 months and 4.7 and 10.2 months in the 44 
chemotherapy-naïve and relapsed cases, respectively. Even refractory-relapsed cases 45 
responded to the treatment favorably (27% ORR). The primary toxicity was 46 
myelosuppression with grades 3 or 4 neutropenia in 97% of the patients, which led to 47 
grades 3 or 4 febrile neutropenia in 41% of the patients and two toxic deaths. 48 
Conclusion: This phase II study showed the favorable efficacy and moderate safety 49 
profiles of a topotecan and amrubicin two-drug combination especially in relapsed 50 
patients with ED-SCLC. 51 
 52 
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1. Introduction 55 
The standard regimen for patients with extensive disease small-cell lung cancer 56 
(ED-SCLC) has been cisplatin (CDDP)-based chemotherapy. Combination therapy with 57 
etoposide (ETP) and CDDP or irinotecan and CDDP has been very effective in 58 
previously untreated patients with ED-SCLC.1,2 However, the long-term survival rate is 59 
low; early relapse occurs in the majority of responders, and salvage chemotherapy for 60 
SCLC yields disappointing results.3 The survival of patients with ED-SCLC enrolled in 61 
phase III trials has not improved significantly over the last two decades, clearly 62 
suggesting the need for the further development of novel, more effective agents or 63 
combination regimens.4 64 
Recently, several novel agents have been developed with unique mechanisms of 65 
action and have shown promise in the treatment of SCLC.5 One of them, amrubicin, is 66 
an entirely synthetic anthracycline that inhibits DNA topoisomerase II activity. With an 67 
overall response rate (ORR) of 78.8% and median survival time (MST) of 11.0 months, 68 
amrubicin has demonstrated antitumor activity against previously untreated SCLC.6 69 
Another novel agent, topotecan, is a semi-synthetic water-soluble analog of 70 
camptothecin that inhibits DNA topoisomerase I activity. It, too, has shown favorable 71 
antitumor activity against SCLC with an ORR of 39% and MST of 9.0 months.7 72 
Previously, we conducted a phase I trial to determine the safety and efficacy of a 73 
two-drug combination chemotherapeutic regimen of amrubicin and topotecan in patients 74 
with untreated or relapsed ED-SCLC.8 75 
Based on the results of the phase I trial, we conducted a phase II trial of 76 
amrubicin and topotecan in patients with untreated or relapsed ED-SCLC to determine 77 
5 
the ORR primarily. Secondary objectives were to investigate toxicity, progression-free 78 
survival (PFS), and overall survival. 79 
 80 
2. Materials and methods 81 
2.1. Eligibility criteria 82 
Patients were recruited based on the following eligibility criteria: pathologically 83 
proven SCLC; chemotherapy-naïve ED-SCLC defined as distant metastasis, 84 
contralateral hilar lymph node metastasis or malignant pleural effusion,9 or relapsed 85 
disease (one prior regimen allowed); Eastern Cooperative Oncology Group (ECOG) 86 
performance status (PS) of 0 to 3; age ≤ 75 years; presence of measurable lesions; no 87 
chemotherapy within 4 weeks before entry in the study; adequate hematological [white 88 
blood cell (WBC) count ≥ 3000/μL, neutrophil count ≥ 1500/μL, hemoglobin level ≥ 89 
8.5 g/dL, platelet count ≥ 10 × 104/μL], renal (serum creatinine level ≤ 1.5 mg/dL), and 90 
hepatic (total bilirubin level ≤ 1.5 mg/dL, serum transaminases ≤ 2.5 × upper limit of 91 
normal range) function; and adequate pulmonary reserves [arterial oxygen pressure 92 
(PaO2) ≥ 60 Torr]. Relapsed cases included those with sensitive relapse (an interval of 93 
at least 90 days after the completion of first-line chemotherapy) and 94 
chemotherapy-refractory relapse (no response to first-line chemotherapy or relapse 95 
within 90 days after the completion of first-line chemotherapy). Patients with 96 
symptomatic brain metastasis, double cancer, massive effusion requiring drainage, or 97 
severe comorbidities (e.g., uncontrolled diabetes, heart disease, infectious disease, or 98 
pulmonary fibrosis) were ineligible. Pretreatment evaluations included a complete 99 
history, physical examination, laboratory tests, chest radiography, electrocardiography, 100 
computed tomography (CT) of the chest and abdomen, magnetic resonance imaging 101 
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(MRI) of the brain, and a radionuclide bone scan. Staging was conducted according to 102 
the tumor, node, metastasis system.10 Positron emission tomography (PET)/CT was also 103 
used for staging in some cases. 104 
All patients gave written consent, and the protocol was approved by the 105 
institutional review board of each participating institute and performed in accordance 106 
with the amended 2000 version of the World Medical Association’s Declaration of 107 
Helsinki. 108 
 109 
2.2. Treatment scheme 110 
The doses and schedules of both agents were based on phase I trial results.8 111 
Topotecan was diluted in 100 mL of physiological saline and administered 112 
intravenously as a 1-h infusion at a dose of 0.75 mg/m2 on days 1 through 5. After 113 
completing the topotecan infusion, amrubicin was diluted in 20 mL of physiological 114 
saline and administered intravenously as a 5-min bolus injection at a dose of 35 mg/m2 115 
on days 3 through 5. Each patient was pre-medicated with intravenous dexamethasone 116 
and granisetron. 117 
The treatment was repeated every four weeks for up to four cycles unless disease 118 
progression or unacceptable toxicity was observed, or the patient refused further 119 
treatment. Initiation of the next cycle of chemotherapy was delayed until the WBC and 120 
platelet count recovered to ≥ 3000/μL and ≥ 10 × 104/μL, respectively, and 121 
non-hematologic toxicities resolved to ≤ grade 1. Patients were permitted to receive any 122 
other chemotherapy for SCLC after completing or discontinuing the regimen. If 123 
hematological toxicity of grade 4 lasting more than 4 days or non-hematological 124 
toxicity ≥ grade 3 was observed in a prior cycle, the amrubicin dose was reduced each 125 
7 
cycle by 5 mg/m2. The protocol treatment was stopped if patients developed the same 126 
toxicities after the second dose reduction. If grade 4 leukopenia, grade 4 neutropenia, or 127 
febrile neutropenia was observed, use of granulocyte colony-stimulating factor (G-CSF) 128 
was permitted. 129 
 130 
2.3. Assessment of antitumor activity and toxicity 131 
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 guidelines 132 
were applied to evaluate responses. Patients were evaluated for SCLC, with tumor 133 
assessments at baseline every two cycles, and at the end of treatment. The best overall 134 
response was defined as the best response recorded from the start of treatment until 135 
disease progression or recurrence. Complete and partial responses were confirmed by 136 
two observations no less than 4 weeks apart. A determination of stable disease required 137 
disease stabilization for at least 6 weeks. In this study, we also defined the disease 138 
control rate (DCR) as the proportion of patients with complete and partial responses and 139 
stable disease.11 All toxicities were graded according to the National Cancer Institute 140 
Common Terminology Criteria for Adverse Events v3.0. Patients were monitored 141 
closely for signs of cardiotoxicity during the study, and an electrocardiogram was 142 
required at the start of treatment. 143 
 144 
2.4. Statistical Analysis 145 
The primary endpoint of this study was the overall response rate (ORR), and 146 
secondary end points were PFS, overall survival, and the toxicity profile. The efficacy 147 
of topotecan and amrubicin combination therapy was assessed separately for 148 
chemotherapy-naïve and relapsed patients. For chemo-naïve cases, assuming that a 90% 149 
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ORR in eligible patients would indicate potential usefulness, whereas a 70% ORR 150 
would constitute the lower limit of interest, with α = 0.10 and β = 0.10, the estimated 151 
accrual was 25 patients. For relapsed cases, assuming that a 30% ORR would indicate 152 
potential usefulness, whereas a 10% ORR would constitute the lower limit of interest, 153 
with α = 0.10 and β = 0.10, the estimated accrual was also 25 patients. This regimen was 154 
to be rejected when < 12 and < 2 of the first 16 cases had an ORR at the interim analysis, 155 
for the chemotherapy-naïve and salvage cases, respectively. With an assumed 10% 156 
dropout rate, the number of patients needed was 28 each. Overall survival was defined 157 
as the interval between the date of enrollment in this study and death or the last 158 
follow-up visit. PFS was defined as the interval between the date of enrollment and the 159 
date of the first observation of disease progression or death from any cause. The 160 
survival distribution was estimated using the Kaplan-Meier method. All statistical 161 
analyses were conducted with STATA/SE version 10.0 software (College Station, TX). 162 
 163 
3. Results 164 
Patient characteristics and treatment delivery 165 
A total of 59 consecutive patients with 31 chemotherapy-naïve or 28 relapsed 166 
ED-SCLC were enrolled from eight institutions. Their demographics are shown in 167 
Table 1. All patients were assessable for efficacy and safety. The median number of 168 
treatment cycles was four (range 1–7 cycles) and three (range 1–8 cycles) in the 169 
chemotherapy-naïve and relapsed cases, respectively. Among patients who received 170 
only three or less cycles of treatment, the most common reason for treatment cessation, 171 
was disease progression (15 of the 29 patients). At the time of analysis, 29 of 31 (94%) 172 
chemotherapy-naïve and 24 of 28 (86%) relapsed patients developed disease 173 
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progression. Of these, 26 chemotherapy-naïve and 11 relapsed patients received salvage 174 
chemotherapies: platinum-based doublet (n = 19), non-platinum-based doublet (n = 5), 175 
and monotherapy (n = 2) in the chemotherapy-naïve patients, and platinum-based 176 
doublet (n = 4), non-platinum doublet (n = 1), and monotherapy (n = 6) in the relapsed 177 
patients.  178 
 179 
Response 180 
Due to early febrile neutropenia-related death (day 20, cycle 1), one patient 181 
received no formal response assessment. The planned interim analysis revealed this 182 
regimen had potent activity (13 and 6 responders) and the committee decided to 183 
continue further patient accrual in the chemotherapy-naïve and salvage settings, 184 
respectively. The ORR of chemotherapy-naïve patients was 74% (95% confidence 185 
interval (CI) 55–88%). This did not satisfy the initial setting of the lower limit of 186 
interest (70%), and thus the primary endpoint was not met for this population. By 187 
contrast, 43% of relapsed patients responded to the study treatment (95% CI 24–63%), 188 
which clearly met the lower limit of interest (10%). 189 
In 28 relapsed patients, the ORR and DCR were 53% and 82%, respectively, for 190 
the sensitive-relapsed cases, and 27% and 82%, respectively, for the refractory-relapsed 191 
cases (Table 2).  192 
 193 
Survival  194 
All the patients were assessable for the survival analysis. At the time of this 195 
analysis (January, 2010), 11 patients were still alive, and median follow-up time was 196 
43.2 months ranging from 4.3 to 75.9 months. The median PFS time was 5.3 months for 197 
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the chemotherapy-naïve cases and 4.7 months for relapsed cases (Table 3 and Figure 1). 198 
The overall median survival time (MST) was 14.9 and 10.2 months for the 199 
chemotherapy-naïve and relapsed cases, respectively. When relapsed cases were 200 
classified by the type of relapse pattern, the median progression-free survival was 5.8 201 
months in patients with sensitive relapse and 3.3 months in patients with refractory 202 
relapse. The overall median survival time was 10.2 and 10.5 months in sensitive and 203 
refractory relapse, respectively (Figure 2). 204 
 205 
Safety 206 
Adverse events of grade 3 or worse are listed in Table 4. Myelosuppression was 207 
the primary adverse event. Grades 3 and 4 neutropenia, thrombocytopenia, and anemia 208 
were observed in 97%, 51%, and 42% of the patients, respectively. Median duration of 209 
neutropenia was five days. G-CSF was administered in 50 patients (85%), whereas 14 210 
patients received blood transfusion. Grade 3 or worse non-hematological toxicities 211 
including anthracycline-related cardiac toxicities were relatively mild, except for febrile 212 
neutropenia, which resulted in two treatment-related deaths (chemo-naïve setting and 213 
refractory relapsed setting in one each). 214 
 215 
4. Discussion 216 
In this relatively small study, the combination of amrubicin and topotecan 217 
yielded an ORR of 74% and 43% in the chemotherapy-naïve and relapsed cases, 218 
respectively. The survival data were also promising with a median PFS time and MST 219 
of 5.3 and 14.9 months and 4.7 and 10.2 months in the chemotherapy-naïve and 220 
relapsed cases, respectively. Even refractory-relapsed cases responded to this treatment 221 
11 
(27% ORR). The major observed toxicity was myelosuppression. Grades 3 and 4 222 
neutropenia occurred in 97% of the patients, resulting in grades 3 and 4 febrile 223 
neutropenia in 41% of the patients. 224 
In a first-line setting, platinum plus irinotecan or etoposide is considered a 225 
standard treatment for ED-SCLC and approved in Japan. These regimens produce an 226 
ORR of 68 to 84%, a median PFS of 4.8 to 6.9 months, and a MST of 9.4 to 12.8 227 
months.1 Combination therapy consisting of cisplatin plus topotecan or cisplatin plus 228 
amrubicin has also been evaluated and has similar effects (56 to 88% ORR, 7.0-month 229 
median PFS, and 10.3 to 13.6 month-MST.12,13 In this study, combination therapy of 230 
topotecan and amrubicin produced less favorable efficacy than we initially expected 231 
although it yielded a nearly identical efficacy with a 74% ORR, 5.3-month median PFS, 232 
and 14.9 month-MST. 233 
With regard to relapsed patients, Inoue et al. conducted a randomized phase II 234 
trial of amrubicin versus topotecan for relapsed SCLC patients and reported an ORR of 235 
38% and 13% in amrubicin monotherapy and topotecan monotherapy, respectively.14 236 
The respective median PFS times and MSTs were 3.5 and 8.1 months (amrubicin 237 
monotherapy) and 2.2 and 8.4 months (topotecan monotherapy). Based on our post-hoc 238 
sub-analysis stratifying relapse type, the efficacy of the amrubicin and topotecan 239 
combination therapy seemed more favorable especially in the refractory-relapsed cases 240 
when compared simply with each single therapy (27% vs. 0–17% ORR, 82% vs. 241 
18–68% DCR, 3.3 vs. 1.5–2.6-month median PFS, and 10.5 vs. 5.3-5.4-month MST).14 242 
Another trial also showed somewhat lower response rate of amrubicin monotherapy for 243 
refractory cases.15 This might suggest some synergistic effects of the two drugs despite 244 
the need for further investigations. 245 
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As for the toxicity profiles, neutropenia in our combination therapy was mainly 246 
moderate, which parallels that in our prior phase I trial.8 The occurrence of neutropenia 247 
in 83-93% of the patients undergoing amrubicin monotherapy14,16,17 and 87% of the 248 
patients undergoing topotecan monotherapy14 seemed also similar to our findings. 249 
Furthermore, as in monotherapy, non-hematological toxicities other than febrile 250 
neutropenia of the amrubicin and topotecan combination therapy were generally 251 
tolerable. However, thrombocytopenia, anemia, febrile neutropenia and two toxic deaths 252 
seemed more severe in the combination therapy than the monotherapy6,14,15, suggesting 253 
the need for cautious administration of the doublet therapy. 254 
We have several limitations. Since this was an exploratory phase II single-arm 255 
trial, some selection bias is possible, and a simple comparison between our results and 256 
historical clinical data would be unwarranted and inconclusive. A prospective 257 
comparative study is clearly required. Also, this study design mixes up 3 populations of 258 
patients (untreated, relapsed-sensitive, and relapsed-refractory). Since only 59 patients 259 
enrolled, interpretation of the results is limited by the 3 small subsets of patients. The 260 
two populations of relapsed patients should have been stratified prospectively. 261 
Furthermore, we accrued PS3 patients as well as PS 0-2 patients in this study according 262 
to the previous clinical trial designs18,19. However, to date, this inclusion criterion has 263 
been unusual in most clinical trials, and the great majority of patients accrued in this 264 
study had indeed an excellent PS (0 or 1 in 93%). Thus, the efficacy and safety for PS 265 
2-3 pts would still remain unclear. 266 
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 267 
5. Conclusions 268 
In conclusion, this phase II study showed the favorable efficacy and moderate 269 
safety profiles of a topotecan and amrubicin two-drug combination especially in 270 
relapsed patients with ED-SCLC, while this regimen was less effective in the first-line 271 
setting and not worth while further being evaluated. 272 
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1 
Table 1  Demographics of the patients (n = 59) 1 
 Chemo-naïve (n=31) Relapsed (n=28) 
Age, median (range), years 67 (52-75) 69 (54-73) 
Gender (M / F) 28 / 3 24 / 4 
ECOG PS (0 / 1 / 2) 3 / 26 / 2 11 / 15 / 2 
Smoking history  
(current / former / never)  
11 / 15 / 2 16 / 12 / 3 
Prior irinotecan use - 7 
Prior etoposide use - 21 
Type of treatment setting   
   sensitive relapse - 17 
   refractory relapse - 11 
Sensitive relapse (at ≥ 90 days after completion of first-line chemotherapy). 2 
Chemotherapy-refractory relapse (no response to first-line chemotherapy or relapse 3 
within 90 days after completing first-line chemotherapy). Abbreviations: ECOG PS = 4 
Eastern Cooperative Oncology Group performance status. 5 
6 
2 
Table 2  Subset analysis of efficacy stratified by the type of relapse 7 
    Sensitive relapse 
(n=17) 
Refractory relapse 
(n=11) 
Response No. % No. % 
   complete response 0 0 0 0 
   partial response 9 53 3 27 
   stable disease 5 29 6 55 
   progressive disease 2 12 2 18 
   inevaluable 1* 6 - - 
Overall response rate 9 53 3 27 
Disease control rate 14 82 9 82 
Survival     
median PFS (months) 5.8  3.3  
median OS (months) 10.2  10.5  
1-yr OS (95%CI; %) 38.2 (15.9–60.5) 18.2 (2.9–44.2) 
**Early death. Abbreviations: PFS = progression-free survival, OS = overall survival, 8 
CI = confidence interval. 9 
 10 
3 
Table 3  Objective response and survival 11 
    Chemo-naïve (n=31) Relapsed (n=28) 
Response No. % No. % 
   complete response 1 3 0 0 
   partial response 22 71 12 43 
   stable disease 6 19 11 39 
   progressive disease 2 6 4 14 
   inevaluable - - 1* 3 
Overall response rate 23 74 12 43 
   (95% CI)  (55 to 88)  (24 to 63) 
Disease control rate 29 94 23 82 
Survival     
median PFS (months) 5.3  4.7  
median OS (months) 14.9  10.2  
1-yr OS (95% CI; %) 68.4 (47.8–82.3) 29.9 (14.3–47.4) 
  *Early death. Abbreviations: PFS = progression-free survival, OS = overall survival, CI = 12 
confidence interval.13 
14 
4 
Table 4  Adverse events (grade 3 or worse) 15 
  Grade 3 Grade 4 ≥Grade 3(%) 
Hematologic    
   neutropenia 10 47 97 
   thrombocytopenia 15 15 51 
   anemia 21 4 42 
Non-hematologic    
   fatigue 2 3 9 
   febrile neutropenia 20 4 41 
   nausea/vomiting 2 1 5 
   diarrhea 0 1 2 
   pneumonitis 1 1 3 
   ileus 0 1 2 
 16 
1 
Figure 1 1 
A  B 2 
0.
00
0.
25
0.
50
0.
75
1.
00
P
ro
po
rti
on
 s
ur
vi
vi
ng
0 5 10 15 20 25
Time in months
0.
00
0.
25
0.
50
0.
75
1.
00
P
ro
po
rti
on
 s
ur
vi
vi
ng
0 5 10 15 20 25
Time in months
 3 
4 
2 
Figure 2 5 
A  B 6 
0.
00
0.
25
0.
50
0.
75
1.
00
Pr
op
or
tio
n 
su
rv
iv
in
g
0 5 10 15 20 25
Time in months
0.
00
0.
25
0.
50
0.
75
1.
00
P
ro
po
rti
on
 s
ur
vi
vi
ng
0 5 10 15 20 25
Time in months
 7 
